

## Virtus Health Sciences Fund - Class A

Category  
Health

## Investment Objective &amp; Strategy

## From the investment's prospectus


The investment seeks long-term capital appreciation.

The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio manager considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities.

Past name(s) : Virtus Health Sciences A.

## Volatility and Risk

## Volatility as of 12-31-23



Risk Measures as of 12-31-23			
Port Avg	Rel S&P 500	Rel Cat	
3 Yr Std Dev	16.98	0.97	0.89
3 Yr Beta	0.86	—	1.08

## Principal Risks

Currency, Foreign Securities, Loss of Money, Not FDIC Insured, High Portfolio Turnover, Issuer, Market/Market Volatility, Depositary Receipts, Equity Securities, ETF, Industry and Sector Investing, IPO, Preferred Stocks, Restricted/Illiquid Securities, Shareholder Activity, Small Cap, Mid-Cap


## Important Information

Please refer to the Morningstar Disclosure and Glossary document contained in your plan's eligibility package for additional information. You may always access the most current version of the Disclosure and Glossary at <https://www.voyaretirementplans.com/fundonepagerscolor/DisclosureGlossary.pdf>

Funds or their affiliates may pay compensation to Voya® affiliates offering a fund. Such compensation may be paid out of distribution, service and/or 12b-1 fees that are deducted from the fund's assets, and/or may be paid directly by the fund's affiliates. Any fees deducted from fund assets are discussed in the fund's prospectus and disclosed in the fund fact sheet. Because these fees are paid on an on-going basis, over time these fees will increase the cost of your investment and may cost you more than paying other types of sales charges. If offered through a retirement program, additional fees and expenses may be charged under that program. NOT A DEPOSIT. NOT FDIC INSURED. NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY. NOT GUARANTEED BY THE INSTITUTION. MAY GO DOWN IN VALUE.

## Portfolio Analysis

## Composition as of 09-30-23



## Top 10 Holdings as of 09-30-23

	% Assets
Eli Lilly and Co	9.19
UnitedHealth Group Inc	5.04
West Pharmaceutical Services Inc	5.02
AbbVie Inc	4.88
Zoetis Inc Class A	4.66
McKesson Corp	4.49
Danaher Corp	4.42
The Cooper Companies Inc	4.26
Merck & Co Inc	4.14
IDEXX Laboratories Inc	4.08

## Morningstar Style Box™ as of 09-30-23

	% Mkt Cap
Giant	23.40
Large	33.91
Medium	31.40
Small	5.90
Micro	5.39

## Morningstar Equity Sectors as of 09-30-23

	% Fund
Cyclical	0.00
Basic Materials	0.00
Consumer Cyclical	0.00
Financial Services	0.00
Real Estate	0.00
Sensitive	0.00
Communication Services	0.00
Energy	0.00
Industrials	0.00
Technology	0.00
Defensive	100.00
Consumer Defensive	0.00
Healthcare	100.00
Utilities	0.00

## Operations

Gross Prosp Exp Ratio	1.39% of fund assets
Net Prosp Exp Ratio	1.39% of fund assets
Management Fee	0.80%
12b-1 Fee	0.25%
Other Fee	0.01%
Miscellaneous Fee(s)	0.33%
Fund Inception Date	02-05-02
Total Fund Assets (\$mil)	142.4
Annual Turnover Ratio %	75.00
Fund Family Name	Virtus

Waiver Data	Type	Exp. Date	%
—	—	—	—

## Portfolio Manager(s)

Jon Christensen, CFA. Since 2022.  
Chris Armbruster, CFA. Since 2022.

Advisor	Virtus Investment Advisers, Inc.
Subadvisor	Kayne Anderson Rudnick Investment Management LLC

## Notes

The fund's investment adviser has contractually agreed to limit the fund's total operating expenses (excluding certain expenses, such as front-end or contingent deferred sales charges, taxes, leverage and borrowing expenses (such as commitment, amendment and renewal expenses on credit or redemption facilities), interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, unusual or infrequently occurring expenses (such as litigation), acquired fund fees and expenses, and dividend expenses, if any) so that such expenses do not exceed 1.47% for Class A Shares through October 31, 2024. Following the contractual period, the adviser may discontinue these expense reimbursement arrangements at any time. Under certain conditions, the adviser may recapture operating expenses reimbursed and/or fees waived under these arrangements for a period of three years following the date such waiver or reimbursement occurred, provided that the recapture does not cause the fund to exceed its expense limit in effect at the time of the waiver or reimbursement, and any in effect at the time of recapture, after repayment is taken into account.